![Dirk Weber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Dirk Weber
Former positions of Dirk Weber
Companies | Position | Start | End |
---|---|---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Chief Tech/Sci/R&D Officer | 2009-12-31 | 2019-05-31 |
Founder | 2009-12-31 | 2019-05-31 | |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | 2013-12-31 | - |
Founder | 2013-12-31 | - |
Statistics
International
Finland | 2 |
Switzerland | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Health Technology |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Dirk Weber
- Experience